Receipt of mRNA COVID-19 vaccines preconception and during pregnancy and risk of self-reported spontaneous abortions, CDC v-safe COVID-19 Vaccine Pregnancy Registry 2020-21.

COVID-19 vaccine mRNA vaccine miscarriage pregnancy pregnancy loss spontaneous abortion vaccine safety

Journal

Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035

Informations de publication

Date de publication:
09 Aug 2021
Historique:
pubmed: 18 8 2021
medline: 18 8 2021
entrez: 17 8 2021
Statut: epublish

Résumé

There is continuing public concern about the safety of COVID-19 vaccination during pregnancy. While there is no compelling biological reason to expect that mRNA COVID-19 vaccination (either preconception or during pregnancy) presents a risk to pregnancy, data are limited. It is, however, well documented that SARS-CoV-2 infection during pregnancy is associated with severe illness and increased risk of adverse pregnancy outcomes. Among recognized pregnancies in high-income countries, 11-16% end in spontaneous abortion (SAB). People enrolled in v-safe, a voluntary smartphone-based surveillance system, who received a COVID-19 vaccine preconception or during pregnancy were contacted by telephone to enroll in the v-safe pregnancy registry. V-safe pregnancy registry participants who received at least one dose of an mRNA COVID-19 vaccine preconception or prior to 20 weeks' gestation and who did not report a pregnancy loss before 6 completed weeks' gestation were included in this analysis to assess the cumulative risk of SAB using Life Table methods. Among 2,456 pregnant persons who received an mRNA COVID-19 vaccine preconception or prior to 20 weeks' gestation, the cumulative risk of SAB from 6-19 weeks' gestation was 14.1% (95% CI: 12.1, 16.1%). Using direct age standardization to the selected reference population, the age-standardized cumulative risk of SAB was 12.8% (95% CI: 10.8-14.8%). When compared to the expected range of SABs in recognized pregnancies, these data suggest receipt of an mRNA COVID-19 vaccine preconception or during pregnancy is not associated with an increased risk of SAB. These findings add to accumulating evidence that mRNA COVID-19 vaccines during pregnancy are safe.

Sections du résumé

Background UNASSIGNED
There is continuing public concern about the safety of COVID-19 vaccination during pregnancy. While there is no compelling biological reason to expect that mRNA COVID-19 vaccination (either preconception or during pregnancy) presents a risk to pregnancy, data are limited. It is, however, well documented that SARS-CoV-2 infection during pregnancy is associated with severe illness and increased risk of adverse pregnancy outcomes. Among recognized pregnancies in high-income countries, 11-16% end in spontaneous abortion (SAB).
Methods UNASSIGNED
People enrolled in v-safe, a voluntary smartphone-based surveillance system, who received a COVID-19 vaccine preconception or during pregnancy were contacted by telephone to enroll in the v-safe pregnancy registry. V-safe pregnancy registry participants who received at least one dose of an mRNA COVID-19 vaccine preconception or prior to 20 weeks' gestation and who did not report a pregnancy loss before 6 completed weeks' gestation were included in this analysis to assess the cumulative risk of SAB using Life Table methods.
Results UNASSIGNED
Among 2,456 pregnant persons who received an mRNA COVID-19 vaccine preconception or prior to 20 weeks' gestation, the cumulative risk of SAB from 6-19 weeks' gestation was 14.1% (95% CI: 12.1, 16.1%). Using direct age standardization to the selected reference population, the age-standardized cumulative risk of SAB was 12.8% (95% CI: 10.8-14.8%).
Conclusions UNASSIGNED
When compared to the expected range of SABs in recognized pregnancies, these data suggest receipt of an mRNA COVID-19 vaccine preconception or during pregnancy is not associated with an increased risk of SAB. These findings add to accumulating evidence that mRNA COVID-19 vaccines during pregnancy are safe.

Identifiants

pubmed: 34401872
doi: 10.21203/rs.3.rs-798175/v1
pmc: PMC8366802
pii:
doi:

Types de publication

Preprint

Langues

eng

Commentaires et corrections

Type : CommentIn

Déclaration de conflit d'intérêts

The authors have no conflicts of interest to disclose.

Auteurs

Lauren Head Zauche (L)

Centers for Disease Control and Prevention.

Bailey Wallace (B)

Centers for Disease Control and Prevention.

Ashley N Smoots (AN)

Centers for Disease Control and Prevention.

Christine K Olson (CK)

Centers for Disease Control and Prevention.

Titilope Oduyebo (T)

Centers for Disease Control and Prevention.

Shin Y Kim (SY)

Centers for Disease Control and Prevention.

Emily E Peterson (EE)

Centers for Disease Control and Prevention.

Jun Ju (J)

Centers for Disease Control and Prevention.

Jennifer Beauregard (J)

Centers for Disease Control and Prevention.

Allen J Wilcox (AJ)

National Institute of Environmental Health Sciences.

Charles E Rose (CE)

Centers for Disease Control and Prevention.

Dana Meaney-Delman (D)

Centers for Disease Control and Prevention.

Sascha R Ellington (SR)

Centers for Disease Control and Prevention.

Classifications MeSH